Table 1.
Characteristics of Study Population
| Variable | Category | CCS(n=319) | Controls (n=208) | p-value |
|---|---|---|---|---|
| Age | Years (mean ± SEa) | 14.5 ± 0.1 | 13.6 ± 0.2 | <0.001 |
| Sexb | Male | 171 (54%) | 112(54%) | 0.93 |
| Female | 148 (46%) | 96 (46%) | ||
| Race/Ethnicityb,c | White Non-Hispanic | 274 (86%) | 194(93%) | <0.001 |
| Others | 45 (14%) | 14 (7%) | ||
| White Hispanic | 4(1%) | 4 (2%) | ||
| Black | 14(4%) | 3(1%) | ||
| Others | 27 (9%) | 7 (4%) | ||
| Tanner | Tanner Stage (mean ± SEa) | 3.6 ± 0.1 | 3.3 ± 0.1 | 0.07 |
| 1b | 33(10%) | 33(17%) | ||
| 2 | 54(17%) | 32 (15%) | ||
| 3 | 39 (12%) | 36(17%) | ||
| 4 | 88 (28%) | 45 (22%) | ||
| 5 | 105(33%) | 60 (29%) | ||
| Diagnosis b | Leukemia | NA | ||
| Acute Lymphoblastic | 102 (32%) | |||
| Acute Myeloid | 8 (3%) | |||
| CNS | NA | |||
| Glial tumors | 38 (12%) | |||
| Retinoblastoma | 16(5%) | |||
| Other tumorsd | 15 (5%) | |||
| Neuroectodermal tumors | 13(4%) | |||
| Solid Tumors | NA | |||
| Sarcoma | 32 (10%) | |||
| Renal | 30 (9%) | |||
| Neuroblastoma | 23 (7%) | |||
| Other tumorse | 22 (7%) | |||
| Non-Hodgkin's Lymphoma | 20 (6%) | |||
| Time from diagnosis to study | Years (mean ± SEa) (range) | |||
| All CCS | 10.1 ± 0.2(5.0–17.8) | NA | ||
| Leukemia | 10.2 ± 0.3 (5.1–16.0) | |||
| CNS | 9.7 ± 0.4 (4.3–17.1) | |||
| Solid Tumors | 10.2 ± 0.3 (5.5–17.8) |
a
SE: Standard Error
b
Data displayed as n (%)
c
Per low cell counts, White Hispanic, Black, and Other categories collapsed for the comparison between CCS and controls.